Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Predictive Biomarker for Contrast Induced Nephropathy, in Moderate Risk Patients after Cardiac Catheterization

Hany Taha Asklny, Nasser M Taha, Adel Hamdy and Sherif Magdy
Cardiovascular Department, Faculty of Medicine, Minia University, Egypt
*Corresponding author: Hany Taha Asklny, Faculty of Medicine, Minia University, Egypt, Tel: 00201001180345; E-mail: hany_t_asklny@yahoo.com
Received date: April 06, 2018; Accepted date: June 20, 2018; Published date: June 27, 2018
Copyright: ©2018 Asklny HT, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Contrast-induced nephropathy (CIN) is an acute kidney insult (AKI) defined as creatinine (SCr) increase 48 to 72 h after intravenous contrast. Because most subjects undergoing invasive cardiac procedures are discharged within 24 h, SCr is unsuitable for CIN detection. This study compares between serum NGAL, and SCr in moderate risk patients after coronary angiography with/without intervention for the occurrence of CIN.

Methods: This was a prospective provisional study carried out from January 2015 to July 2016, in the department of Cardiology, El-Minia University Hospital (EGYPT). 42 moderate risk Subjects (Mehran Score 6 to 10 with estimated 14% risk of developing CIN) undergoing elective coronary angiography with/without intervention were enrolled. Serum NGAL was assessed before and 4 h post-procedure. SCr was measured before and 48 h post-procedure. CIN was defined as SCr increase >25% or >0.5 mg/dL from baseline after coronary angiography within 48 h, without explanation or the presence of any cause.

Results: 30 males and 12 females with mean age 54.92 ± 10.14 (36-73) years and mean baseline SCr 1.01 ± 0.25 mg/dL (0.6-1.8) were enrolled. A contrast volume with mean 161.9 ± 76.35 ml (100-300) was administered. CIN was found in twelve subjects (28.6%). Included subjects were classified into those with and without CIN, NGAL was significantly elevated in subjects with CIN versus those without 4 h after coronary intervention 172.69 ± 70.48 (50-280 ng/mL) vs. 104.19 ± 53.03 (75-350 ng/mL) (P<0.001). Using a cutoff value of >174 ng/mL, 4-h NGAL was excellent predictor of CIN with 91.67% sensitivity, 93.33% specificity, 84.6% PPV, 92.86% NPV, 92.86% Accuracy and 92.86 area under (ROC) curve. Baseline demographics show no difference between those with and without CIN among study groups. Serum NGAL at 4 h post procedure (P<0.001) used as a predictor of the occurrence of CIN among study groups.

Conclusions: Serum NGAL measured 4 h following coronary angiography with/without intervention after intravenous contrast administration can be used as a novel and helpful biomarker for the occurrence of CIN in moderate risk patient. The percentage of CIN incidence (28.6%) in this study in moderate risk patients highlight the useful use of serum NGAL 4 h post procedure measurement to predict, intervene and may prevent CIN.

Keywords: Acute kidney insult; Coronary angiography; Contrast-induced nephropathy; Neutrophil gelatinase-associated lipocalin

Introduction

CIN is now the one of the causes of acute kidney insult which occurs after intravenous contrast infusion in-hospital and is responsible for approximately 10% of all cases of iatrogenic renal disease [1]. Contrast-induced nephropathy (CIN) is an important cause of hospital-acquired acute renal failure and has a poor prognosis [2]. CIN is defined as the impairment of renal function-measured as either increase in serum creatinine (SCr) about 25% from baseline or a 0.5 mg/dL (44 µmol/L) increase in absolute SCr value-within 48-72 h after intravenous contrast administration [3] incidence of CIN after intravenous contrast administration is widely variable in the literature, depending on the baseline risk factors and the definition used of this clinical event [4]. It affects between 1% and 2% of the general population and up to 50% of high-risk subgroups following coronary angiography (CA) or percutaneous coronary intervention (PCI) [5]. The current definition of the CIN is based on the absolute or relative increase in the serum creatinine [6], SCr elevation is relatively slow and is influenced by extra-renal factors [1]. Levels peak 2-3 days after contrast medium exposure [7], therefore the use of SCr for the detection of AKI delays therapeutic intervention by about 48 h following the insult to the kidney. Hence, considerable efforts had been put into the search for new biomarkers as early indicators of AKI [8]. One of the promising candidate biomarkers is neutrophil gelatinase-associated lipocalin (NGAL), a 25 kDa siderophore binding protein [9], NGAL has been identified as a sensitive and specific biomarkers for predicting cardiac surgery-associated acute kidney injury [10]. NGAL is indicative of distal nephron damage, as it is massively upregulated in the ascending limb of the loop of Henle, distal tubule and collecting duct [11]. NGAL has emerged as an early, sensitive, non-invasive biomarker for predicting CI-AKI in different cardiovascular conditions [12]. With the continued use of serum creatinine as a marker of kidney function, Treatment regimens for AKI have been unsuccessful over the years, also due to the incomplete understanding of the pathogenesis and biomarkers for early detection,
in addition to poor clinical trial design [13]. Our study therefore aimed to evaluate the role of serum NGAL as a new marker for early detection of CIN after elective coronary angiography with/without intervention, compared with the traditional marker SCr, and to determine the frequency of CIN in these patients.

Patients and Methods

Study design

This was a prospective study carried out from January 2015 to July 2016. In the department of cardiology, El-Minia University hospital (Egypt), 42 moderate risk Subjects (Mehran score 6 to 10 with estimated 14% risk of developing CIN) in the cath-lab undergoing elective coronary angiography with/without intervention were enrolled. All patients received intravenous (IV) normal saline at a rate of 1 mL/kg for 12 h pre-procedure for in-patients, 3 mL/kg for 3 h pre-procedure for our patients, serum NGAL was measured before and 4 h post-procedure. SCr was measured before and 48 h post-procedure. CIN was defined as SCr increase >25% or <0.5 mg/dL from baseline after coronary angiography with or without intervention within 48 h, without explanation or the presence of any cause.

Measurement of NGAL and other variables

The serum for NGAL was first diluted 20-fold using calibrator diluents and then assayed using an enzyme-linked immune-sorbent assay (ELISA) kit from R&D Systems (Minneapolis, Minnesota). The SCr levels were determined by using kinetic Jaffe method (Thermo Scientific Kone lab Prime 60i Clinical Chemistry Analyzer) [14].

Statistical analysis

Data was statistical analyzed by using SPSS_20 software package. Categorical data was presented in the form of frequency and percentage. Quantitative data were expressed in the form of mean; SD. One way ANOVA test was used to test the significance between groups for quantitative variables however Chi-square (χ²) was used for qualitative data. Duncan multi-comparison test was used. Person correlation coefficient was used to get the correlation between variables. Probability (p value) was considered as significant if <0.05. Univariate and multivariate stepwise multiple logistic regression analysis was undertaken to assess predictors of CIN. A receiver operating characteristic (ROC) curve was generated and the area under the curve (AUC) was used to calculate the sensitivity and specificity for plasma NGAL measurements to predict the occurrence of CIN at varying cut-off values, and to quantify the accuracy of plasma NGAL as a biomarker (Medcalc, version 12.2.1). An AUC of 0.5 is no better than expected by chance, whereas a value of 1.0 signifies a perfect biomarker.

Results

Forty-two moderate risk patients (Mehran Score 6 to 10 with estimated 14% risk of developing CIN) in the Cath-Lab undergoing elective coronary angiography with/without intervention, male/female 30/12, mean age 54.92 ± 10.14 (36-73) years, with mean baseline SCr 0.5 is no better than expected by chance, whereas a value of 1.0 signifies a perfect biomarker.

According to our results subjects were classified into those with and without CIN. Baseline patient demographic data shows no significant differences were noted between CIN and non-CIN groups (Table 1). There was a statistically significant increase in SCr from baseline and at 48 h post-procedure in all 42 patients: 1.01 ± 0.25 mg/dl (0.6-1.8) and 1.2 ± 0.29 mg/dl (0.8-2.4), p ≤ 0.001, with a statistically significant increase in SNGAL from baseline then at 4 h post-procedure: 104.19 ± 53.03 ng/ml (50-280) and 172.69 ± 70.48 ng/ml (75-350), p ≤ 0.001 (Table 2).

Table 1: Statistical comparison between subjects with and without CIN as regard to age and sex.

| Nephropathy | P value |
|-------------|---------|
| No          | Yes     |
| (n=30)      | (n=12)  |

| Age         |          |
|-------------|----------|
| Range       | (36-67)  |
| Mean ± SD   | 53.66 ± 8.94 |
| Sex         |          |
| Male        | 21 (70%) |
| Female      | 9 (30%)  |
|            | 1 (25%)  |

Table 2: The data shows plasma creatinine at baseline and at 48 h after catheterization and plasma NGAL at baseline and at 4 h after catheterization.

A statistically significant differences were noted between non-CIN and CIN groups in SNGAL at baseline and at 4 h post-procedure: at baseline 88.86 ± 31.21 ng/ml (55-170) and 142.5 ± 75.33 ng/ml (50-280), p=0.005, at 4 h post 139.1 ± 38.92 ng/ml (75-240) and 256.66 ± 61.24 ng/ml (130-350), p ≤ 0.001 (Table 3).

| Nephropathy | P value |
|-------------|---------|
| No          | Yes     |
| (n=30)      | (n=12)  |

| NGAL pre-catheterization |          |
|--------------------------|----------|
| Range                    | (55-170) |
| Mean ± SD                | 88.86 ± 31.21 |

| NGAL after catheterization |          |
|----------------------------|----------|
| Range                      | (50-280) |
| Mean ± SD                  | 142.5 ± 75.33 |

J Clin Exp Cardiolog, an open access journal
ISSN:2155-9880

Volume 9 • Issue 7 • 1000599
There were statistically significant differences regarding EF, NGAL, pre, 4 h post catheterization, CHF, diabetes, contrast volume and total Mehran score among study subjects with and without CIN by using simple logistic regression analysis (Table 4).

| Variable     | OR     | 95% CI       | P value |
|--------------|--------|--------------|---------|
| EF>50%       | 0.79   | 0.69-0.91    | <0.001’|
| NGAL pre     | 1.02   | 1.004-1.04   | 0.014’  |
| NGAL post    | 1.04   | 1.02-1.07    | 0.001’  |
| CHF          | 5.18   | 1.15-23.29   | 0.032’  |
| Anemia       | NA     | NA           | NA      |
| Diabetes     | 6      | 1.32-27.19   | 0.020’  |

Table 4: Shows simple logistic regression analysis of study variables in CIN and non-CIN groups

Multiple stepwise logistic regression analysis revealed that 4 h NGAL post as the most predicted significant variable (Table 5).

Table 5: Multiple stepwise logistic regression analysis

Table 6: ROC curve analyses for prediction of CIN for 4 h post NGAL and contrast volume.

Discussion

Our study demonstrates that measuring plasma NGAL via enzyme-linked immune-sorbent assay (ELISA) 4 h after intravenous contrast administration to be a clinically useful, novel, early and helpful biomarker for the early prediction of CIN in moderate risk patient undergoing elective catheterization biomarker in the early prediction of CIN. Therefore, plasma NGAL appears to be a powerful early biomarker of CIN that precedes the increase in Scr by several hours. Furthermore, the high incidence of the occurrence of CIN observed and detected in this study (28.6%) makes attention to the importance of early prediction of CIN by a rapid new biomarker as plasma NGAL 4 h post procedure measurement.

Prior studies demonstrate the usefulness of measurement of NGAL as an early biomarker of CI-AKI in different scenarios, especially after coronary angiography with or without intervention after contrast administration; however the optimal timing for its determination following coronary angiography has not yet been well elucidated. Our results demonstrate that excellent performance of plasma NGAL with overall AUC-ROC of 0.933 for CIN, when measured 4 h post procedure, with a sensitivity of 91.6% and specificity of 93.3% these findings was in agreement was that found in a meta-analysis studies that found an overall AUC-ROC of 0.894 for CIN prediction, when plasma or urine NGAL was measured within 6 h after contrast administration for coronary procedures with or without interventions [15].

In contrast to our results the increase in urinary NGAL measured by a research-based assay at 24 h post-procedure was significantly high in CIN group when compared to the non CIN group in a Chinese Study where CIN was detected in 8.7% of adult with normal renal function undergoing coronary angiography [16].

Recently and In marked contrast to our findings urinary NGAL failed as an early predictor of CIN in a study from Austria conducted on 617 patients with chronic kidney disease (CKD) undergoing intravascular angiography, only 10 of them exhibited a significant rise of uNGAL exceeding the threshold for randomization and only one single patient out of these developed CI-AKI [17] this may be explained by observation reported by Mori and Nakao “the forest fire theory” which assume that increased NGAL in CKD is the...
consequence of its sustained production by inflamed but viable tubular cells [18].

Recently also, in agreement with this study, 8% of patients developed CIN in Indian study conducted on 240 patients with baseline creatinine <1.4 mg/dl. Urinary NGAL at 4 hours post coronary angiogram was an excellent predictor for contrast induced acute kidney injury with sensitivity and specificity of 94.7% and 99.1% respectively, and with positive and negative predictive values of 90% and 99.5% respectively [19].

With CIN, using the same definition as a 25% increase in SCr from baseline another study also from Egypt, significant increase was present in serum NGAL 4 and 24 h after coronary interventions among adults with normal SCr was detected in 6.7% of the participants. Devarajan used serum NGAL 4 h post-procedure in agreement with our study with another definition and longer follow up of NGAL after 24 h [20].

The relatively high incidence of CIN reported in this study 28% should be taken into account for the result interpretation and analysis and this is may be due to variations in study designs and methodology used for NGAL measurements either plasma or urine for CIN definition.

The baseline renal function and also the normal pre-procedure renal function both considered an important predictive performance of NGAL results.

Our study population consisted of subjects at moderate risk for CIN involved only elective catheterization excluding emergent ones that are usually performed in subjects with major co-morbidities and potentially at higher risk of CIN.

An additional strength of our study is that all subjects started with low levels of plasma NGAL. In the current study, there was no significant difference in the baseline SCr between the two groups (CIN/non-CIN), and also all included subjects started the study with low levels of plasma NGAL. Our study design allowed a direct comparison between any alterations in the level of NGAL concentration when compared to changes in SCr, which is considered the current reference standard test for the definition of CIN. So the magnitude of any rise for NGAL from baseline found in our study supports that present in other literature data that NGAL highly discriminatory biomarker with a good cut-off values that allow for risk assessment and stratification with a wide dynamic range.

In the current study plasma NGAL was measured instead of urine NGAL which is more accurate and precise for early detection of CIN if it is revolutionized in clinical medicine as the use of troponins for the early diagnosis of acute myocardial infarction and the value of B-type natriuretic peptide for prognostication in acute coronary syndromes.

Limitations

Although this is a single center trial and the number is relatively small, yet statistical analysis was valid for the conclusions taken. However, a large number might be needed for firmer conclusions.

Subjects at higher risk of CIN such as patients with advanced CKD, emergency patients, and thermodynamically unstable must be included in further studies.

Conclusion

Serum NGAL measured by ELISA 4 hours following coronary angiography with/without intervention after intravenous contrast administration can be used as a novel and helpful biomarker for the occurrence and prediction of CIN in moderate risk patient undergoing elective catheterization.

References

1. Gallagher S, Knight C (2011) Contrast-induced nephropathy in primary percutaneous coronary intervention. Heart 97: 1723-1725.
2. Nüñez J, Miñana G, Santas E, Bertomeu-González V (2015) Cardiorenal Syndrome in Acute Heart Failure: Revisiting Paradigms. Rev Esp Cardiol 68: 426-435.
3. Kidney Disease Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. (2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Inter., Suppl 2: 1-138.
4. Ozcan OU, Adanir Er H, Olec S, Ustun EE, Gerede DM, et al. (2015) Impact of metabolic syndrome on development of contrast-induced nephropathy after elective percutaneous coronary intervention among non-diabetic patients. Clin Cardiol 38: 150-156.
5. Mehran R, Nikolsky E (2006) Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl S11-15.
6. Khatami MR, Nikravan N, Salari-Far M, Davoudi S, Pahlavan-Sabbagh MR (2016) A comparison of definitions of contrast-induced nephropathy in patients with normal serum creatinine. Saudi J Kidney Dis Transpl 27: 94-100.
7. European Society of Urogenital Radiology Group (2016) Non-renal adverse reactions. ESUR.
8. Pickerling J, Balib A, Nejat M, Endre Z (2011) New considerations in the design of clinical trials of acute kidney injury. Clin Invest 5: 637-650.
9. Haase-Fielitz A, Haase M, Devarajan P (2014) Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem 51: 335-351.
10. Zhou F, Luo Q, Wang L, Han I (2016) Diagnostic value of neutrophil gelatinase-associated lipocalin for early diagnosis of cardiac surgery-associated acute kidney injury: a meta-analysis. Eur J Cardiothorac Surg 49: 746-755.
11. Singer E, Marklö I, Paragas N, Barasch I, Dragun D (2013) Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. Acta Physiol. (Oxf.) 207: 663-672.
12. Connolly M, McEneaney D, Menown I, Morgan N, Harbison M (2015) Novel biomarkers of acute kidney injury after contrast coronary angiography. Cardiol Rev 23: 240-246.
13. Bonventre JV, Basile D, Liu KD, McKay D, Molitoris BA, et al. (2013) AKI: a path forward. Clin J Am Soc Nephrol 8: 1606-1608.
14. Rickli H, Renou K, Ammann P, Fehr T, Brunner-La Rocca HP, et al. (2004) Time course of serial cystatinC levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol 60: 98-102.
15. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A, The NGAL Meta-analysis Investigator Group (2009) Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 54: 1012-1024.
16. Ling W, Zhaohui N, Ben H, Leyi G, Jianping L, et al. (2008) Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract 108: c176-c181.
17. Shaker OG, El-Shehaby A, El-Khatib M (2010) Early diagnostic markers for contrast nephropathy in patients undergoing coronary angiography. Angiology 61: 731-736.
18. Solomon RJ, Mehran R, Natarajan MK, Doucet S, Katholi RE, et al. (2009) Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol 4: 1162-1169.

19. Devarajan P (2010) Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med 4: 265-280.

20. Devarajan P (2008) Neutrophil gelatinase-associated lipocalin: an emerging troponin for kidney injury. Nephrol Dial Transplant 23: 3737-3743.